Neoleukin Therapeutics, Inc. Skyrocketed
Neoleukin Therapeutics, Inc. (NLTX:NASDAQ) jumped higher at $0.72, representing a gain of 35.8%. On Thu, Mar 09, 2023, NLTX:NASDAQ touched a New 2-Week High of $0.72. The stock appeared on our News Catalysts scanner on Wed, Mar 08, 2023 at 05:38 PM in the 'INVESTOR UPDATE' category. From Thu, Feb 23, 2023, the stock recorded 50.00% Up Days and 63.64% Green Days
About Neoleukin Therapeutics, Inc. (NLTX:NASDAQ)
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. It generates immunotherapies using de novo protein design technology. The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Top 10 Gainers:
- Ocean Biomedical Inc Com (OCEA:NASDAQ), 125.16%
- Allied Healthcare Products, Inc. (AHPI:NASDAQ), 71.43%
- Intuitive Machs Inc Cl A (LUNR:NASDAQ), 57.8%
- Decarbonization Plus Acquisition Corporation IV (DCRD:NASDAQ), 40.52%
- Neoleukin Therapeutics, Inc. (NLTX:NASDAQ), 35.8%
- Peak Bio Inc Com (PKBO:NASDAQ), 32.82%
- Toro Corp. (TORO:NASDAQ), 28.31%
- Unicycive Therapeutics Inc. (UNCY:NASDAQ), 27.16%
- Digital Brands Group Inc. (DBGI:NASDAQ), 25.62%
- Build-A-Bear Workshop, Inc. (BBW:NYSE), 21.04%